Until relatively recently, gastroesophageal reflux disease (GERD) was thought to be a relatively trivial problem, and pharmaceutical companies initially had remarkably little interest in clinical trials for GERD. Over the last ten years, GERD therapy has become the subject of intense interest, since reflux disease is now recognized as a major market for antisecretory and prokinetic drugs. Helicobacter pylori has a peculiar relationship to GERD. There has been some concern that PPIs given to patients with H. pylori might accelerate development ofsevere atrophic gastritis. It is also now known that eradication of H. pylori may increase symptomatic GERD (possibly as a result of increased gastric acid secretion once the bacteria have been eliminated).
refluxfor up to 90 minutes. Esophageal pH profiling is known to be an excellent surrogatefor clinical efficacy of GERD drugs, particularly in erosive esophagitis. Years ago, famotidine normalized esophageal mucosal exposure to pH < 4.0 only when administered in doses of 40 mg twice a day. Subsequent studies confirmed that multiple daily dosing of histamine-2 receptor antagonists (H2RAs) was mandatory for GERD treatment, with clear dose-response relationships for each agent.
Proton pump inhibitors (PPIs) have each been carefully assessed in terms esophageal Helicobacter pylori has a peculiar relationship to GERD. There has been some concern that PPIs given to patients with H. pylori might accelerate development ofsevere atrophic gastritis. It is also now known that eradication of H. pylori may increase symptomatic GERD (possibly as a result of increased gastric acid secretion once the bacteria have been eliminated).
New data confirm nocturnal breakthrough ofacid secretion and esophageal acid exposure in threefourths ofpatients on omeprazole 20 mg twice daily. This nocturnal acidity can be controlled more effectively with a nighttime dose ofan H2RA than with a third dose ofomeprazole. [4] . Therefore, although H2RAs and prokinetic medications can be extremely satisfactory for control of heartburn, PPIs uniformly surpass even ultra-high doses of H2RAs or the combination of H2RA's with prokinetic medications for treating the more severe endoscopic grades of erosive esophagitis.
Antacids, considered archaic by many physicians, are actually surprisingly effective at promptly elevating esophageal pH and continuing to neutralize acid at the esophageal mucosal level for up to 90 min after dosing [5] . There is currently great interest in the development of suitable H2RA-antacid combinations to allow both the prompt treatment of heartburn as well as the prevention of subsequent heartburn episodes for many hours. No such combination product currently exists, but the growing over-the-counter market for lowdose or even prescription-level H2R's will stimulate further ambitious development of effective and reliable chewable formulations of antacids and H2RAs.
Helicobacter pylori has been a major scientific focus in gastroenterology for the last several years, and it is clear that most "peptic" ulcers can be attributed to gastric mucosa infected with H. pylori. However, at least at the present time, there appears to be no causal relationship between H. pylori and GERD. Indeed, there is some evidence that the effective eradication of H. pylori, a known inhibitor of gastric acid secretion, may worsen the symptoms of gastroesophageal reflux following gastric or duodenal ulcer healing and bacterial eradication. A fascinating controversy arose over the past two years in relation to the development of chronic atrophic gastritis following long-term PPI therapy of GERD. Ernst Kuipers' important 1996 article in the New England Journal of Medicine suggested that Dutch GERD patients infected with H. pylori receiving omeprazole maintenance treatment developed accelerated atrophic gastritis versus a group of Swedish patients who had been managed surgically [6] . Subsequently, it has become clear that the control group may not have been perfectly matched to the medically treated patients; and an FDA-sponsored consensus conference has disputed the relationship between PPI therapy and development of chronic atrophic gastritis. Indeed, careful review of omeprazole and lansoprazole maintenance therapy data by both current PPI sponsors thus far has failed to substantiate any linkage between PPI treatment and any chronic gastric atrophy. Nevertheless, since H. pylori itself can lead to chronic atrophic gastritis, discussions of therapeutic options continue.
It seems clear that there will now be "PPI Wars" similar to the strong conflicts between the various H2RAs that occurred in the past. Omeprazole is now known to be potentially variable in its metabolism, and many patients fail to decrease pathological esophageal acid exposure with usual doses of omeprazole. Indeed, recent data confirm that three-fourths of all patients will have significant periods of nocturnal acid exposure despite omeprazole 20 mg twice a day. Somewhat surprising is the finding that this nocturnal acid "breakthrough" responds better to a bedtime dose of an H2RA vs. an additional 20 mg of omeprazole [7] . Both pantoprazole and rabeprazole seem to produce more rapid onset and more complete gastric acid inhibition than omeprazole, and this differentiation seems sure to impact future marketing. The precise levels of dosing required for the newer PPIs have yet to be determined, particularly as applicable to refractory GERD patients.
Control of esophageal pH may require multiple doses of all available PPIs, particularly in more difficult cases of GERD. However, the PPI that can be most cost effective will undoubtedly prosper in the increasingly price-sensitive pharmaceutical market. In general, this will entail once daily dosing for the majority of patients.
The PPI that can demonstrate such cost effectiveness should gamer a substantial marketing advantage.
In summary, it is clear that pH profiling of antisecretory drugs in terms of their effects on gastric and esophageal acidity will continue to be critical to their posi-tioning in the competitive marketplace, and investigators working in this arena should have much additional work ahead. For GERD, the reduction of esophageal acid exposure certainly can be considered as a surrogate measure for clinical efficacy.
